Clinical Trials Browser

Phase 1 × idelalisib × 90 days × Clear all

NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell